You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

Details for Patent: 7,465,800

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,465,800 protect, and when does it expire?

Patent 7,465,800 protects REVLIMID and is included in one NDA.

This patent has two hundred and ninety-eight patent family members in forty countries.

Summary for Patent: 7,465,800

Title:	Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
Abstract:	Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.
Inventor(s):	Jaworsky; Markian S. (Hopewell, NJ), Chen; Roger Shen-Chu (Edison, NJ), Muller; George W. (Bridgewater, NJ)
Assignee:	Celgene Corporation (Summit, NJ)
Application Number:	10/934,863
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,465,800
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 7,465,800

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-005	Dec 21, 2011	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-001	Dec 27, 2005	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-002	Dec 27, 2005	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-003	Jun 29, 2006	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-006	Jun 5, 2013	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-004	Jun 29, 2006	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 7,465,800

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2105135	⤷ Sign Up	1590004-6	Sweden	⤷ Sign Up
European Patent Office	2105135	⤷ Sign Up	C300717	Netherlands	⤷ Sign Up
European Patent Office	2105135	⤷ Sign Up	CA 2015 00006	Denmark	⤷ Sign Up
European Patent Office	2105135	⤷ Sign Up	92642	Luxembourg	⤷ Sign Up
European Patent Office	2105135	⤷ Sign Up	C20150005 00140	Estonia	⤷ Sign Up
European Patent Office	2105135	⤷ Sign Up	212 50002-2015	Slovakia	⤷ Sign Up
European Patent Office	2105135	⤷ Sign Up	122015000013	Germany	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.